CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals

Nature Medicine

Volumn 14, Issue 4, 2008, Pages 413-420

  Ahuja, Sunil K ^a,b,c   Kulkarni, Hemant ^a,b   Catano, Gabriel ^a,b   Agan, Brian K ^d,e,f   Camargo, Jose F ^a,b   He, Weijing ^a,b   O'Connell, Robert J ^d,e   Marconi, Vincent C ^d,e,f   Delmar, Judith ^d,e,f   Eron, Joseph ^g   Clark, Robert A ^a,b   Frost, Simon ^h,i   Martin, Jeffrey ^j   Ahuja, Seema S ^a,b   Deeks, Steven G ^j   Little, Susan ^h   Richman, Douglas ^h,i   Hecht, Frederick M ^j   Dolan, Matthew J ^d,e,f  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e WILFORD HALL MEDICAL CENTER   (United States)

^f SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HLA ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; GENE CONTROL; GENE DOSAGE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGENICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; T CELL DEPLETION; VIRUS INHIBITION;

ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CC; COHORT STUDIES; GENE DOSAGE; GENOTYPE; HIV INFECTIONS; HLA ANTIGENS; HUMANS; PROSPECTIVE STUDIES; RECEPTORS, CCR5; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 41849143395     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1741     Document Type: Article

References (50)

1. Douek, D.C., Picker, L.J. & Koup, R.A. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21, 265-304 (2003).
2. Rodriguez, B. et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. J. Am. Med. Assoc. 296, 1498-1506 (2006).
3. Dolan, M.J. et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat. Immunol. 8, 1324-1336 (2007).
4. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis. 44, 441-446 (2007).
5. Grabar, S. et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133, 401-410 (2000).
6. Tarwater, P.M. et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 168-175 (2001).
7. Hunt, P.W. et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17, 1907-1915 (2003).
8. Moore, D.M. et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquir. Immune Defic. Syndr. 40, 288-293 (2005).
9. Valdez, H. et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16, 1859-1866 (2002).
10. Kaufmann, G.R. et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41, 361-372 (2005).
11. + cell counts: a EuroSIDA study. J. Infect. Dis. 194, 633-641 (2006).
12. Mehandru, S. et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3, e484 (2006).
13. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J. Infect. Dis. 181, 946-953 (2000).
14. Ledergerber, B. et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral drug classes. Lancet 364, 51-62 (2004).
15. Deeks, S.G. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. J. Am. Med. Assoc. 286, 224-226 (2001).
16. Kaufmann, G.R. et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163, 2187-2195 (2003).
17. + T-cell count. J. Acquir. Immune Defic. Syndr. 36, 702-713 (2004).
18. Tenorio, A.R. et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J. Acquir. Immune Defic. Syndr. 34, 491-496 (2003).
19. + cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann. Intern. Med. 140, 256-264 (2004).
20. Grabar, S. et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 39, 284-292 (2005).
21. Zhang, Z.Q. et al. The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P. Virology 320, 75-84 (2004).
22. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946-954 (1997).
23. Lifson, J.D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584-2593 (2000).
24. Nibbs, R.J., Yang, J., Landau, N.R., Mao, J.H. & Graham, G.J. LD78b, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J. Biol. Chem. 274, 17478-17483 (1999).
25. Gonzalez, E. et al. Race-specific HIV-1 disease - modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA 96, 12004-12009 (1999).
26. Mangano, A. et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J. Infect. Dis. 183, 1574-1585 (2001).
27. Gonzalez, E. et al. The influence of CCL3L1 gene - containing segmental duplications on HIV-1/AIDS susceptibility. Science 307, 1434-1440 (2005).
28. Martin, M.P. et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907-1911 (1998).
29. Kaslow, R.A., Dorak, T. & Tang, J.J. Influence of host genetic variation on susceptibility to HIV type 1 infection. J. Infect. Dis. 191 (Suppl 1), S68-S77 (2005).
30. Carrington, M. & O'Brien, S.J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551 (2003).
31. Nguyen, L. et al. Frequent human leukocyte antigen class I alleles are associated with higher viral load among HIV type 1 seroconverters in Thailand. J. Acquir. Immune Defic. Syndr. 37, 1318-1323 (2004).
32. Rauch, A. et al. HLA-Bw4 homozygosity is associated with an impaired CD4-T-cell recovery after initiation of antiretroviral therapy. Clin. Infect. Dis. (in the press).
33. Brumme, Z.L. et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195, 1694-1704 (2007).
34. Moore, D.M. et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 20, 371-377 (2006).
35. Weber, R. et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166, 1632-1641 (2006).
36. Gutierrez, F. et al. Clinical Outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS ONE 1, e89 (2006).
37. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296 (2006).
38. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46, 72-77 (2007).
39. Valdez, H., Purvis, S.F., Lederman, M.M., Fillingame, M. & Zimmerman, P.A. Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy. J. Am. Med. Assoc. 282, 734 (1999).
40. Yamashita, T.E. et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 15, 735-746 (2001).
41. Kasten, S. et al. Positive influence of the Δ32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1-infected patients. Eur. J. Med. Res. 5, 323-328 (2000).
42. O'Brien, T.R. et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 14, 821-826 (2000).
43. Holmberg, S.D., Palella, F.J., Jr, Lichtenstein, K.A. & Havlir, D.V. The case for earlier treatment of HIV infection. Clin. Infect. Dis. 39, 1699-1704 (2004).
44. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-128 〈http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGl. pdf〉, accessed 29 February 2008 (Department of Health and Human Services, 29 January 2008).
45. Pahwa, S. Role of common γ chain-utilizing cytokines for immune reconstitution in HIV infection. Immunol. Res. 38, 373-386 (2007).
46. Hecht, F.M. et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194, 725-733 (2006).
47. + cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS 12, 2107-2113 (1998).
48. Kaslow, R.A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2, 405-411 (1996).
49. Tang, J. et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 16, 2275-2284 (2002).
50. Carrington, M., Nelson, G. & O'Brien, S.J. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol. Lett. 79, 131-140 (2001).